Eli Gilboa

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Hyaluronic Acid

Regulatory T Cells

Immune Response

Top Venues

Cancer immunology, immunotherapy : CII

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Emily S Clark, Ana Paula Benaduce, Wasif N Khan, Olivier Martinez, Eli Gilboa
Vaccination against neoantigens induced in cross-priming cDC1 in vivo. Cancer immunology, immunotherapy : CII 73 (1) (2024)
Emily S Clark, Ana Paula Benaduce, Wasif N Khan, Olivier Martinez, Eli Gilboa
Vaccination against neoantigens induced in cross-priming cDC1 in vivo. Cancer immunology, immunotherapy : CII 73 (1) (2024)
Emily S Clark, Ana Paula Benaduce, Wasif N Khan, Olivier Martinez, Eli Gilboa
Vaccination against neoantigens induced in cross-priming cDC1 in vivo. Cancer immunology, immunotherapy : CII 73 (1) (2024)
Emily S Clark, Ana Paula Benaduce, Wasif N Khan, Olivier Martinez, Eli Gilboa
Vaccination against neoantigens induced in cross-priming cDC1 in vivo. Cancer immunology, immunotherapy : CII 73 (1) (2024)
Emily S Clark, Ana Paula Benaduce, Wasif N Khan, Olivier Martinez, Eli Gilboa
Vaccination against neoantigens induced in cross-priming cDC1 in vivo. Cancer immunology, immunotherapy : CII 73 (1) (2024)
Emily S Clark, Ana Paula Benaduce, Wasif N Khan, Olivier Martinez, Eli Gilboa
Vaccination against neoantigens induced in cross-priming cDC1 in vivo. Cancer immunology, immunotherapy : CII 73 (1) (2024)
Emily S Clark, Ana Paula Benaduce, Wasif N Khan, Olivier Martinez, Eli Gilboa
Vaccination against neoantigens induced in cross-priming cDC1 in vivo. Cancer immunology, immunotherapy : CII 73 (1) (2024)
Siddharth Mehra, Vanessa T Garrido, Austin R Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang J Ban, Jashodeep Datta, Eli Gilboa, Nipun B Merchant, Nagaraj S Nagathihalli
Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer. Cancer research communications 3 (7) (2023)